Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Atherosclerosis. 2014 Oct 17;237(2):609–617. doi: 10.1016/j.atherosclerosis.2014.09.036

Fig. 4.

Fig. 4

Ezetimibe blocks intestinal NPC1L1-mediated increases in hepatic and biliary cholesterol. A) Total cholesterol (TC), free cholesterol (FC) and cholesterol ester (CE). The amount of cholesterol ester was calculated by subtracting free cholesterol from total cholesterol and multiplying by 1.67 to convert to cholesterol ester mass. B) Triglycerides (n = 8–12). C) Relative hepatic mRNA levels of cholesterol-regulated genes (n = 5). HMGCR, HMG-CoA reductase; HMGCS, HMG-CoA synthase. D), E) Biliary concentrations and molar ratios of cholesterol, phospholipids and bile acids (n = 8–12). F) Immunoblots of ABCG5 and receptor-associated protein (RAP) (as an internal control) in the liver membrane preparations. Groups not sharing a common superscript letter are significantly different (P < 0.05).